Summary
Over recent years botulinum toxin type A has emerged as a safe and effective treatment for a number of previously refractory conditions associated with excessive muscle activity. The list of indications is expanding, but at present it is generally considered to be the treatment of choice for focal dystonias such as blepharospasm, torticollis, laryngeal dystonia, and oromandibular dystonia, as well as hemifacial spasm, strabismus, and some forms of limb spasticity. Carefully targeted intramuscular injections of a small amount of the toxin block the release of acetylcholine at the neuromuscular junction, producing a chemical denervation, with the aim of reducing excessive muscle activity without producing significant functional weakness. In some situations electrophysiological assessment and localisation of the muscles for injection is necessary.
Treatment is symptomatic, with effects lasting 3 to 4 months and most patients requiring up to 4 injections per year to maintain the beneficial effect. Appropriate use of the toxin requires both an understanding of the physiological action of the potential muscles involved in each situation, together with a knowledge of the likely dose necessary to reduce muscle activity to the required level. Botulinum toxin represents a major advance in the management of these conditions, many of which responded poorly to previously available forms of therapy.
Similar content being viewed by others
References
Therapeutics and Technology Subcommittee of the American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin A in treating neurologic disorders. Neurology 1990; 40: 1332–6
Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186–94
Scott AB. Botulinum toxin injections into extra ocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044–9
Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 1992; 239: 16–20
Quinn N, Hallet M. Dose standardisation of botulinum toxin. Lancet 1989; 1: 964
Cornelia CL, Buchman AS, Tanner CM, et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992; 42: 878–82
Lange DJ, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987; 10: 552–5
Eiston J. Botulinum toxin treatment of blepharospasm. Adv Neurol 1988; 50: 579–81
Stell R, Thompson PD, Marsden CD. Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1988; 51: 920–3
Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990; 40: 277–80
Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992; 326: 349–50
Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991; 100: 85–9
Lees AJ. Botulinum toxin: useful in adult onset focal dystonias. BMJ 1992; 305: 1169–70
Brin MF, Fahn S, Moskowitz C, et al. Localised injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987; 2: 237–54
Jankovic J, Schwartz PA. Botulinum toxin treatment of tremors. Neurology 1991; 41: 1185–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hughes, A.J. Botulinum Toxin in Clinical Practice. Drugs 48, 888–893 (1994). https://doi.org/10.2165/00003495-199448060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199448060-00005